Assessment of Seroprevalence of SARS-CoV-2 and Risk Factors Associated With COVID-19 Infection Among Outpatients in Virginia.

Autor:	Rogawski McQuade ET; Division of Infectious Diseases and International Health, University of Virginia, Charlottesville.; Department of Public Health Sciences, University of Virginia, Charlottesville., Guertin KA; Department of Public Health Sciences, University of Virginia, Charlottesville., Becker L; Division of Infectious Diseases and International Health, University of Virginia, Charlottesville., Operario D; Division of Infectious Diseases and International Health, University of Virginia, Charlottesville., Gratz J; Division of Infectious Diseases and International Health, University of Virginia, Charlottesville., Guan D; Research and Clinical Trial Analytics Team, Division of Quality Performance Improvement, University of Virginia, Charlottesville., Khan F; Research and Clinical Trial Analytics Team, Division of Quality Performance Improvement, University of Virginia, Charlottesville., White J; Division of Infectious Diseases and International Health, University of Virginia, Charlottesville., McMurry TL; Department of Public Health Sciences, University of Virginia, Charlottesville., Shah B; Inova Heart and Vascular Institute, Inova Health System, Falls Church, Virginia., Garofalo S; Inova Heart and Vascular Institute, Inova Health System, Falls Church, Virginia., Southerland M; Inova Heart and Vascular Institute, Inova Health System, Falls Church, Virginia., Bear K; Inova Heart and Vascular Institute, Inova Health System, Falls Church, Virginia., Brush J; Office of Clinical Research, Sentara Healthcare, Norfolk, Virginia., Allen C; Office of Clinical Research, Sentara Healthcare, Norfolk, Virginia., Frayser A; Division of Infectious Diseases, Virginia Commonwealth University, Richmond., Vokes R; Division of Infectious Diseases, Virginia Commonwealth University, Richmond., Pershad R; Division of Infectious Diseases, Virginia Commonwealth University, Richmond., Peake L; Virginia Department of Health, Richmond., deFilippi C; Inova Heart and Vascular Institute, Inova Health System, Falls Church, Virginia., Barackman K; Office of Clinical Research, Sentara Healthcare, Norfolk, Virginia., Bearman G; Division of Infectious Diseases, Virginia Commonwealth University, Richmond., Bidanset A; Carilion Clinic, Roanoke, Virginia., Farrell F; Carilion Clinic, Roanoke, Virginia., Trump D; Virginia Department of Health, Richmond., Houpt ER; Division of Infectious Diseases and International Health, University of Virginia, Charlottesville.
Jazyk:	angličtina
Zdroj:	JAMA network open [JAMA Netw Open] 2021 Feb 01; Vol. 4 (2), pp. e2035234. Date of Electronic Publication: 2021 Feb 01.
DOI:	10.1001/jamanetworkopen.2020.35234
Abstrakt:	Importance: Data from seroepidemiologic surveys measuring severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exposure in diverse communities and ascertaining risk factors associated with infection are important to guide future prevention strategies. Objective: To assess the prevalence of previous SARS-CoV-2 infection across Virginia and the risk factors associated with infection after the first wave of coronavirus disease 2019 (COVID-19) infections in the US. Design, Setting, and Participants: In this statewide cross-sectional surveillance study, 4675 adult outpatients presenting for health care not associated with COVID-19 in Virginia between June 1 and August 14, 2020, were recruited to participate in a questionnaire and receive venipuncture to assess SARS-CoV-2 serology. Eligibility was stratified to meet age, race, and ethnicity quotas that matched regional demographic profiles. Main Outcomes and Measures: The main outcome was SARS-CoV-2 seropositivity, as measured by the Abbott SARS-CoV-2 immunoglobulin G assay. Results: Among 4675 adult outpatients (mean [SD] age, 48.8 [16.9] years; 3119 women [66.7%]; 3098 White [66.3%] and 4279 non-Hispanic [91.5%] individuals) presenting for non-COVID-19-associated health care across Virginia, the weighted seroprevalence was 2.4% (95% CI, 1.8%-3.1%) and ranged from 0% to 20% by zip code. Seroprevalence was notably higher among participants who were Hispanic (10.2%; 95% CI, 6.1%-14.3%), residing in the northern region (4.4%; 95% CI, 2.8%-6.1%), aged 40 to 49 years (4.4%; 95% CI, 1.8%-7.1%), and uninsured (5.9%; 95% CI, 1.5%-10.3%). Higher seroprevalence was associated with Hispanic ethnicity (adjusted odds ratio [aOR], 3.56; 95% CI, 1.76-7.21), residence in a multifamily unit (aOR, 2.55; 95% CI, 1.25-5.22), and contact with an individual with confirmed COVID-19 infection (aOR, 4.33; 95% CI, 1.77-10.58). The sensitivity of serology results was 94% (95% CI, 70%-100%) among those who reported receiving a previous polymerase chain reaction test for COVID-19 infection. Among 101 participants with seropositive results, 67 individuals (66.3%) were estimated to have asymptomatic infection. These data suggested a total estimated COVID-19 burden that was 2.8-fold higher than that ascertained by PCR-positive case counts. Conclusions and Relevance: This large statewide serologic study estimated that 2.4% of adults in Virginia had exposure to SARS-CoV-2, which was 2.8-fold higher than confirmed case counts. Hispanic ethnicity, residence in a multifamily unit, and contact with an individual with confirmed COVID-19 infection were significant risk factors associated with exposure. Most infections were asymptomatic. As of August 2020, the population in Virginia remained largely immunologically naive to the virus.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu